Why the study?
What is the clinical significance of patient-prosthesis mismatch after transcatheter aortic valve implantation?
What is the clinical significance of patient-prosthesis mismatch after transcatheter aortic valve implantation?
This review highlights the adverse clinical consequences of patient-prosthesis mismatch, emphasizing its relevance in the context of transcatheter aortic valve implantation.
Answers are grounded in this paper and cite their sources.
Alerts to PPM risks after TAVI; leaves open whether prevention strategies improve outcomes.
Patientprosthesis mismatch (PPM) was described by Rahimtoola in 1978 (1) as an effective prosthetic valve area that is less than that of a normal human valve. Despite technical efforts to optimize valve prostheses, their rheological properties are not comparable with those of native human valves and aortic stenosis will occur in a normally functioning prosthesis that is too small for the patient. PPM is associated with decreased regression of left ventricular hypertrophy, reduced coronary flow reserve, increased incidence of congestive heart failure, diminished functional capacity, and increased risk of early and late mortality (2,3). This paper is a brief review of the clinical significance of PPM, with reference to transcatether aortic valve implantation (TAVI).
No takes yet. Share an insight, caveat, or question.
Kukucka et al. (2012) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: